1. Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; 2. Department of Pharmacy, Beijing Hospital, Beijing 100730, China
Abstract��OBJECTIVE To review systematically the effect and safety of tofacitinib for patients with moderate to severe psoriasis. METHODS Relevant studies were published until May 16, 2018 were identified through The Cochrane Library, PubMed, Embase, Clinical Trials.gov, CNKI, Wanfang, CBM and other web knowledge databases. Two reviewers independently screened literatures according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of the included studies. Then we performed statistical analyses using the Review Manager 5.2 and Stata 12.0 software. RESULTS Eight randomized controlled trials that compared tofacitinib vs placebo were included in the study. The final Meta-analysis included a total of 3 308 patients with psoriasis. Tofacitinib was associated with reductions in psoriasis area and severity index 75% (RR 3.27, 95%CI1.79-5.98, P=0.000 1), psoriasis area and severity index 90% (RR 12.61, 95%CI7.66-20.76, P<0.000 01), physician��s global assessment (RR 4.38, 95%CI3.51-5.47, P<0.000 01). A safety analysis showed that tofacitinib increased the risk of hypercholesterolemia (RR 2.57, 95%CI1.22-5.38, P=0.01) and tended to associate with increasing the risk of herpes zoster (RR 3.20, 95%CI0.86-11.91, P=0.08). CONCLUSION Tofacitinib is effective and relatively safe for patients with psoriasis. Therefore, tofacitinib may be a promising treatment option for patients with moderate to severe psoriasis who had previously an inadequate response to the conventional synthetic treatment.
�Ű���, �Ϻ���, ����Ƽ, ����, ������. �з��沼�����С��ض���м������Ч����ȫ�Ե�ϵͳ���ۺ�Meta����[J]. �й�ҩѧ��־, 2019, 54(8): 665-670.
ZHANGAi-ling, MENGHai-yang, YANGLi-ping, HUXin, ZHANGXiao-jian. The Effect and Safety of Tofacitinib for Patients with Moderate to Severe Psoriasis: A Meta-Analysis of Randomized Controlled Trials. Chinese Pharmaceutical Journal, 2019, 54(8): 665-670.
PARISI R, SYMMONS D P, GRIFFITHS C E, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence[J]. J Invest Dermatol, 2013, 133(2):377-385.
[2]
MENTER A, KORMAN N J, ELMETS C A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions[J]. J Am Acad Dermatol, 2011, 65(1):137-174.
[3]
SALVARANI C, MACCHIONI P, OLIVIERI I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis[J]. J Rheumatol, 2001, 28(10):2274-2282.
[4]
OLIVIERI I, SALVARANI C, CANTINI F, et al. Therapy with cyclosporine in psoriatic arthritis[J]. Semin Arthritis Rheum, 1997, 27(1):36-43.
[5]
KALTWASSER J P, NASH P, GLADMAN D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial[J]. Arthritis Rheum, 2004, 50(6):1939-1950.
[6]
CLEGG D O, REDA D J, MEJIAS E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study[J]. Arthritis Rheum, 1996, 39(12):2013-2020.
[7]
CLEGG D O, REDA D J, ABDELLATIF M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veterans affairs cooperative study[J]. Arthritis Rheum, 1999, 42(11):2325-2329.
[8]
BLACK R L, O��BRIEN W M, VANSCOTT E J, et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients[J]. JAMA, 1964:189743-189747.
[9]
LI J H, HU A, ZHENG W J, et al. Screening of target protein of triptolide on psoriasis by molecular docking[J]. Chin Pharm J (�й�ҩѧ��־), 2014, 49(13):1133-1138.
[10]
PIROWSKA M M, GOZDZIALSKA A, LIPKO-GODLEWSKA S, et al. Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis[J]. Postepy Dermatol Alergol, 2015, 32(4):250-254.
[11]
GROUP CMASASDBP. Chinese psoriasis treatment expert consensus (2014 Edition)[J]. Chin Dermatol J(�л�Ƥ������־), 2014, 47(3):213-215.
[12]
NALDI L, GRIFFITHS C E. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks[J]. Br J Dermatol, 2005, 152(4):597-615.
[13]
HSU L, ARMSTRONG A W. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis[J]. J Immunol Res, 2014,(2014):1-7.
[14]
KWATRA S G, DABADE T S, GUSTAFSON C J, et al. JAK inhibitors in psoriasis: a promising new treatment modality[J]. J Drugs Dermatol, 2012, 11(8):913-918.
[15]
ZHANG J, TSAI T F, LEE M G, et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study[J]. J Dermatol Sci, 2017, 88(1):36-45.
[16]
MEASE P, HALL S, FITZGERALD O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis[J]. N Engl J Med, 2017, 377(16):1537-1550.
[17]
KRUEGER J, CLARK J D, SUAREZ-FARINAS M, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study[J]. J Allergy Clin Immunol, 2016, 137(4):1079-1090.
[18]
GLADMAN D, RIGBY W, AZEVEDO V F, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors[J]. N Engl J Med, 2017, 377(16):1525-1536.
[19]
CAPPELLERI J C, BUSHMAKIN A G, HARNESS J, et al. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity[J]. Qual Life Res, 2013, 22(9):2489-2499.
[20]
CHECCHIO T, AHADIEH S, GUPTA P, et al. Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based Meta-analysis[J]. Clin Pharmacol Ther, 2017, 102(6):1006-1016.
[21]
BASRA M K, HUSSAIN S. Application of the dermatology life quality index in clinical trials of biologics for psoriasis[J]. Chin J Integr Med, 2012, 18(3):179-185.
[22]
HIGGINS J P, ALTMAN D G, GOTZSCHE P C, et al. The cochrane collaboration��s tool for assessing risk of bias in randomised trials[J]. BMJ, 2011,343:d5928.
[23]
PETERS J L, SUTTON A J, JONES D R, et al. Comparison of two methods to detect publication bias in Meta-analysis[J]. JAMA, 2006, 295(6):676-680.
[24]
VALENZUELA F, PAUL C, MALLBRIS L, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a phase 3 study[J]. J Eur Acad Dermatol Venereol, 2016, 30(10):1753-1759.
[25]
VALENZUELA F, PAPP K A, PARISER D, et al. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis[J]. BMC Dermatol, 2015:15(8):1-11.
[26]
PAPP K A, MENTER M A, ABE M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase �� trials[J]. Br J Dermatol, 2015, 173(4):949-961.
[27]
GAO Q, LIANG X, SHAIKH A S, et al. JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases[J]. Current Drug Targets, 2018, 19(5):487-500.
[28]
LJUNG L, RANTAP-DAHLQVIST S. Biological therapies and lipid profile[J]. Eur Musculoskelet Rev, 2011, 6(4):240-247.
[29]
CHARLES-SCHOEMAN C, GONZALEZ-GAY M A, KAPLAN I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist[J]. Semin Arthritis Rheum, 2016, 46(1):71-80.
[30]
WINTHROP K L, NOVOSAD S A, BADDLEY J W, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance[J]. Ann Rheum Dis, 2015, 74(12):2107-2116.
[31]
KUO C M, TUNG T H, WANG S H, et al. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and Meta-analysis of randomized controlled trials[J]. J Eur Acad Dermatol Venereol, 2018, 32(3):355-362.
[32]
SOUTO A, SALGADO E, MANEIRO J R, et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and Meta-analysis[J]. Arthritis Rheumatol, 2015, 67(1):117-127.
[33]
WOLK R, ARMSTRONG E J, HANSEN P R, et al. Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis[J]. J Clin Lipidol, 2017, 11(5):1243-1256.
[34]
WINTHROP K L, LEBWOHL M, COHEN A D, et al. Herpes zoster in psoriasis patients treated with tofacitinib[J]. J Am Acad Dermatol, 2017, 77(2):302-309.
[35]
BING N, ZHOU H Y, ZHANG B H, et al. Genome-wide trans-ancestry Meta-analysis of herpes zoster in rheumatoid arthritis and psoriasis patients treated with tofacitinib[J]. Ann Rheum Dis, 2016, 75(2):256-257.
2019, Vol. 54 
